📊 IBIO Key Takeaways
Is iBio, Inc. (IBIO) a Good Investment?
iBio is a pre-commercial pharmaceutical company with minimal revenue ($100K) and massive operating losses (-$23.8M), burning -$17M annually with no clear path to near-term profitability. While the balance sheet is strong with $47.6M cash and zero debt, fundamentals indicate the company has ~2.8 years of cash runway at current burn rates but lacks sufficient revenue generation to justify ongoing operational scale.
Fundamentals show negligible revenue against very large operating losses and deeply negative free cash flow, producing extreme negative margins. While liquidity is strong and the balance sheet is debt‑free, sustainability depends on rapidly reducing burn and establishing recurring revenue, otherwise external financing risk is high.
iBio, Inc. Key Strengths (IBIO)
- Strong cash position of $47.6M providing ~2.8 years of operational runway
- Excellent liquidity with 11.88x current ratio and zero debt leverage (0x debt/equity)
- Revenue growth of 77.8% YoY shows early commercialization momentum, though from minimal base
- Strong liquidity (cash $28.67M; current ratio 9.04x)
- Debt‑free balance sheet (D/E 0.00x)
- EPS loss narrowed YoY, hinting at some cost discipline
IBIO Stock Risks: iBio, Inc. Investment Risks
- Operating cash burn of -$17.0M annually with free cash flow deeply negative, unsustainable at current burn rate
- Negligible revenue of $100K insufficient to cover operating expenses of -$23.8M, indicating pre-commercial stage with years to profitability
- Pharmaceutical sector execution risk: high R&D costs, regulatory approval uncertainty, and clinical trial failures without visible pipeline progress in fundamentals
- Questionable data quality: Gross Profit ($2.2M) exceeds Revenue ($100K), suggesting potential accounting or data reporting issues
- Large, persistent operating losses and negative FCF (OCF -$10.91M; FCF -$11.45M)
- Tiny revenue base and anomalous gross margin suggest low-quality, non-recurring mix
- Potential dilution/financing need if burn continues
Key Metrics to Watch
- Absolute revenue growth trajectory and path to positive operating cash flow
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestones for pipeline products
- Operating cash burn vs cash runway
- Recurring revenue growth and gross margin quality
iBio, Inc. (IBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.88x current ratio provides a solid financial cushion.
IBIO Profit Margin, ROE & Profitability Analysis
IBIO vs Healthcare Sector: How iBio, Inc. Compares
How iBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is iBio, Inc. Stock Overvalued? IBIO Valuation Analysis 2026
Based on fundamental analysis, iBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
iBio, Inc. Balance Sheet: IBIO Debt, Cash & Liquidity
IBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: iBio, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.50 indicates the company is currently unprofitable.
IBIO Revenue Growth, EPS Growth & YoY Performance
IBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $100.0K | -$4.0M | $-0.06 |
| Q2 2026 | N/A | -$4.0M | $-0.09 |
| Q1 2026 | N/A | -$4.0M | $-0.11 |
| Q3 2025 | N/A | -$3.2M | $-0.49 |
| Q2 2025 | $50.0K | -$4.0M | $-0.48 |
| Q1 2025 | N/A | -$4.0M | $-0.46 |
| Q3 2024 | N/A | N/A | $-0.85 |
| Q2 2024 | N/A | N/A | $-4.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
iBio, Inc. Dividends, Buybacks & Capital Allocation
IBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for iBio, Inc. (CIK: 0001420720)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBIO
What is the AI rating for IBIO?
iBio, Inc. (IBIO) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBIO's key strengths?
Claude: Strong cash position of $47.6M providing ~2.8 years of operational runway. Excellent liquidity with 11.88x current ratio and zero debt leverage (0x debt/equity). ChatGPT: Strong liquidity (cash $28.67M; current ratio 9.04x). Debt‑free balance sheet (D/E 0.00x).
What are the risks of investing in IBIO?
Claude: Operating cash burn of -$17.0M annually with free cash flow deeply negative, unsustainable at current burn rate. Negligible revenue of $100K insufficient to cover operating expenses of -$23.8M, indicating pre-commercial stage with years to profitability. ChatGPT: Large, persistent operating losses and negative FCF (OCF -$10.91M; FCF -$11.45M). Tiny revenue base and anomalous gross margin suggest low-quality, non-recurring mix.
What is IBIO's revenue and growth?
iBio, Inc. reported revenue of $100.0K.
Does IBIO pay dividends?
iBio, Inc. does not currently pay dividends.
Where can I find IBIO SEC filings?
Official SEC filings for iBio, Inc. (CIK: 0001420720) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBIO's EPS?
iBio, Inc. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IBIO's fundamental grade?
Based on our AI fundamental analysis in June 2026, iBio, Inc. has a C grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IBIO stock overvalued or undervalued?
Valuation metrics for IBIO: ROE of -28.9% (sector avg: 15%), net margin of -22,443.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IBIO's AI grade for 2026?
Our dual AI analysis gives iBio, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBIO's free cash flow?
iBio, Inc.'s operating cash flow is $-17.0M, with capital expenditures of $559.0K. FCF margin is -17,549.0%.
How does IBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -22,443.0% (avg: 12%), ROE -28.9% (avg: 15%), current ratio 11.88 (avg: 2).